Graft versus host disease (GVHD) occurs commonly after haematopoietic stem cell transplantation (HSCT). Cutaneous GVHD is a cause of significant morbidity. The use of conventional immunosuppressants leads to increase in the risk of infections and malignancy. Phototherapy is a relatively safe and efficacious alternative for treating chronic GVHD. We aimed to evaluate the effectiveness of psoralen + ultra-violet A (PUVA) therapy in cases of chronic GVHD. We included 10 cases of chronic GVHD, who had undergone HSCT at our centre. A retrospective, observational study analysis was carried out. Parameters like percentage of body surface area involved, percentage reduction in body surface area, number of phototherapy sessions, dose of oral steroid reduced and side effects were evaluated. Out of the total 10 patients, 7 (70%) had clinical features of lichenoid GVHD, while the other 3 (30%) cases had sclerodermatous type of GVHD. The mean time to develop chronic GVHD after bone marrow transplant was 8.25 months. The mean body surface area involved at the time of diagnosis was 53.1%. Seven patients (70%) responded to phototherapy. Five patients (50%) achieved complete remission, while two (20%) had partial remission. One patient (10%) was lost in follow up. One case (10%) died while on PUVA therapy due to relapse of leukaemia. One patient (10%) of lichenoid GVHD relapsed after completion of PUVA therapy. The average number of phototherapy sessions required were 34.6. The average percentage reduction in the dose of oral steroids before and after PUVA therapy was 89.12%. Other immunosuppressants were stopped after an average of 4.57 months in 8 patients. We hereby conclude that PUVA therapy is a much better alternative to the conventional immune suppressing agents for chronic GVHD.